A phase i study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors

John Nemunaitis, Alex W. Tong, Michael Nemunaitis, Neil Senzer, Anagha P. Phadke, Cynthia Bedell, Ned Adams, Yu An Zhang, Phillip B. Maples, Salina Chen, Beena Pappen, James Burke, Daiju Ichimaru, Yasuo Urata, Toshiyoshi Fujiwara

Research output: Contribution to journalArticle

133 Citations (Scopus)

Abstract

A phase I clinical trial was conducted to determine the clinical safety of Telomelysin, a human telomerase reverse transcriptase (hTERT) promoter driven modified oncolytic adenovirus, in patients with advanced solid tumors. A single intratumoral injection (IT) of Telomelysin was administered to three cohorts of patients (1 × 10 10, 1 × 10 11, 1 × 10 12 viral particles). Safety, response and pharmacodynamics were evaluated. Sixteen patients with a variety of solid tumors were enrolled. IT of Telomelysin was well tolerated at all dose levels. Common grade 1 and 2 toxicities included injection site reactions (pain, induration) and systemic reactions (fever, chills). hTERT expression was demonstrated at biopsy in 9 of 12 patients. Viral DNA was transiently detected in plasma in 13 of 16 patients. Viral DNA was detectable in four patients in plasma or sputum at day 7 and 14 post-treatment despite below detectable levels at 24h, suggesting viral replication. One patient had a partial response of the injected malignant lesion. Seven patients fulfilled Response Evaluation Criteria in Solid Tumors (RECIST) definition for stable disease at day 56 after treatment. Telomelysin was well tolerated. Evidence of antitumor activity was suggested.

Original languageEnglish
Pages (from-to)429-434
Number of pages6
JournalMolecular Therapy
Volume18
Issue number2
DOIs
Publication statusPublished - Feb 2010

Fingerprint

Telomerase
Adenoviridae
Neoplasms
Viral DNA
Injections
Safety
Chills
Clinical Trials, Phase I
Sputum
Virion
Fever
Biopsy
Pain
Therapeutics

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Genetics
  • Drug Discovery
  • Pharmacology

Cite this

A phase i study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. / Nemunaitis, John; Tong, Alex W.; Nemunaitis, Michael; Senzer, Neil; Phadke, Anagha P.; Bedell, Cynthia; Adams, Ned; Zhang, Yu An; Maples, Phillip B.; Chen, Salina; Pappen, Beena; Burke, James; Ichimaru, Daiju; Urata, Yasuo; Fujiwara, Toshiyoshi.

In: Molecular Therapy, Vol. 18, No. 2, 02.2010, p. 429-434.

Research output: Contribution to journalArticle

Nemunaitis, J, Tong, AW, Nemunaitis, M, Senzer, N, Phadke, AP, Bedell, C, Adams, N, Zhang, YA, Maples, PB, Chen, S, Pappen, B, Burke, J, Ichimaru, D, Urata, Y & Fujiwara, T 2010, 'A phase i study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors', Molecular Therapy, vol. 18, no. 2, pp. 429-434. https://doi.org/10.1038/mt.2009.262
Nemunaitis, John ; Tong, Alex W. ; Nemunaitis, Michael ; Senzer, Neil ; Phadke, Anagha P. ; Bedell, Cynthia ; Adams, Ned ; Zhang, Yu An ; Maples, Phillip B. ; Chen, Salina ; Pappen, Beena ; Burke, James ; Ichimaru, Daiju ; Urata, Yasuo ; Fujiwara, Toshiyoshi. / A phase i study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. In: Molecular Therapy. 2010 ; Vol. 18, No. 2. pp. 429-434.
@article{3a04f3dc8c384575becaa059f65a3636,
title = "A phase i study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors",
abstract = "A phase I clinical trial was conducted to determine the clinical safety of Telomelysin, a human telomerase reverse transcriptase (hTERT) promoter driven modified oncolytic adenovirus, in patients with advanced solid tumors. A single intratumoral injection (IT) of Telomelysin was administered to three cohorts of patients (1 × 10 10, 1 × 10 11, 1 × 10 12 viral particles). Safety, response and pharmacodynamics were evaluated. Sixteen patients with a variety of solid tumors were enrolled. IT of Telomelysin was well tolerated at all dose levels. Common grade 1 and 2 toxicities included injection site reactions (pain, induration) and systemic reactions (fever, chills). hTERT expression was demonstrated at biopsy in 9 of 12 patients. Viral DNA was transiently detected in plasma in 13 of 16 patients. Viral DNA was detectable in four patients in plasma or sputum at day 7 and 14 post-treatment despite below detectable levels at 24h, suggesting viral replication. One patient had a partial response of the injected malignant lesion. Seven patients fulfilled Response Evaluation Criteria in Solid Tumors (RECIST) definition for stable disease at day 56 after treatment. Telomelysin was well tolerated. Evidence of antitumor activity was suggested.",
author = "John Nemunaitis and Tong, {Alex W.} and Michael Nemunaitis and Neil Senzer and Phadke, {Anagha P.} and Cynthia Bedell and Ned Adams and Zhang, {Yu An} and Maples, {Phillip B.} and Salina Chen and Beena Pappen and James Burke and Daiju Ichimaru and Yasuo Urata and Toshiyoshi Fujiwara",
year = "2010",
month = "2",
doi = "10.1038/mt.2009.262",
language = "English",
volume = "18",
pages = "429--434",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - A phase i study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors

AU - Nemunaitis, John

AU - Tong, Alex W.

AU - Nemunaitis, Michael

AU - Senzer, Neil

AU - Phadke, Anagha P.

AU - Bedell, Cynthia

AU - Adams, Ned

AU - Zhang, Yu An

AU - Maples, Phillip B.

AU - Chen, Salina

AU - Pappen, Beena

AU - Burke, James

AU - Ichimaru, Daiju

AU - Urata, Yasuo

AU - Fujiwara, Toshiyoshi

PY - 2010/2

Y1 - 2010/2

N2 - A phase I clinical trial was conducted to determine the clinical safety of Telomelysin, a human telomerase reverse transcriptase (hTERT) promoter driven modified oncolytic adenovirus, in patients with advanced solid tumors. A single intratumoral injection (IT) of Telomelysin was administered to three cohorts of patients (1 × 10 10, 1 × 10 11, 1 × 10 12 viral particles). Safety, response and pharmacodynamics were evaluated. Sixteen patients with a variety of solid tumors were enrolled. IT of Telomelysin was well tolerated at all dose levels. Common grade 1 and 2 toxicities included injection site reactions (pain, induration) and systemic reactions (fever, chills). hTERT expression was demonstrated at biopsy in 9 of 12 patients. Viral DNA was transiently detected in plasma in 13 of 16 patients. Viral DNA was detectable in four patients in plasma or sputum at day 7 and 14 post-treatment despite below detectable levels at 24h, suggesting viral replication. One patient had a partial response of the injected malignant lesion. Seven patients fulfilled Response Evaluation Criteria in Solid Tumors (RECIST) definition for stable disease at day 56 after treatment. Telomelysin was well tolerated. Evidence of antitumor activity was suggested.

AB - A phase I clinical trial was conducted to determine the clinical safety of Telomelysin, a human telomerase reverse transcriptase (hTERT) promoter driven modified oncolytic adenovirus, in patients with advanced solid tumors. A single intratumoral injection (IT) of Telomelysin was administered to three cohorts of patients (1 × 10 10, 1 × 10 11, 1 × 10 12 viral particles). Safety, response and pharmacodynamics were evaluated. Sixteen patients with a variety of solid tumors were enrolled. IT of Telomelysin was well tolerated at all dose levels. Common grade 1 and 2 toxicities included injection site reactions (pain, induration) and systemic reactions (fever, chills). hTERT expression was demonstrated at biopsy in 9 of 12 patients. Viral DNA was transiently detected in plasma in 13 of 16 patients. Viral DNA was detectable in four patients in plasma or sputum at day 7 and 14 post-treatment despite below detectable levels at 24h, suggesting viral replication. One patient had a partial response of the injected malignant lesion. Seven patients fulfilled Response Evaluation Criteria in Solid Tumors (RECIST) definition for stable disease at day 56 after treatment. Telomelysin was well tolerated. Evidence of antitumor activity was suggested.

UR - http://www.scopus.com/inward/record.url?scp=76349086193&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76349086193&partnerID=8YFLogxK

U2 - 10.1038/mt.2009.262

DO - 10.1038/mt.2009.262

M3 - Article

VL - 18

SP - 429

EP - 434

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 2

ER -